BioCryst 2026 年第三季法說會：ORLADEYO 成長，上修財測

重點摘要

• 2026 年第三季 ORLADEYO 淨營收達 1.748 億美元，其中超過 95% 來自美國。若扣除歐洲區營收，銷售額較去年同期成長 20%。
• 本季包含 CareMed 初次建立庫存所帶來的近 2,000 萬美元貢獻。管理層將其視為一次性效益，並預期未來營收將更緊密地跟隨患者需求。
• Non-GAAP 營業利潤年增 70% 至 8,600 萬美元，non-GAAP 淨利更翻倍成長至 7,100 萬美元。現金及約當現金總計為 3.76 億美元。
• BioCryst 將 2026 年總營收財測上調至 7.15 億至 7.3 億美元，反映授權收入提升與國際 RAPIVAB 訂單增加。ORLADEYO 財測則維持在 6.25 億至 6.45 億美元。
• 2026 全年營業費用財測區間收窄至 4.15 億至 4.25 億美元。重組行動在完全實現後，預計每年將帶來約 3,000 萬至 3,500 萬美元的年化節省額。
• 管理層表示，Navenibart 的關鍵試驗仍按計畫進行，預計將於 2027 年第三季取得 12 個月的主要頂線數據。BCX17725 用於 Netherton 症候群的早期數據預計將於 2026 年底前公佈。

關鍵財務數據

業務與營運表現

ORLADEYO 處方需求維持強勁。管理層表示，新患者處方量持續保持在 2026 年全年高檔水準，而接受治療的患者基數在本季也實現了穩健成長。

BioCryst 於 8 月推出適用於 2 至 11 歲兒童的 ORLADEYO 顆粒劑型。管理層表示初期需求超出預期，涵蓋各年齡層，且患者來源均衡，包含從預防性或僅急性治療轉用的患者，以及初次接受治療的患者。該公司認為，兒童市場的潛在機會可能超過先前討論的 500 名已確診並接受治療的患者族群，不過公司希望在評估穩定狀態需求前取得更多季度的數據。

該公司亦計劃為 12 歲及以上的患者推出已獲批的 150 毫克顆粒劑型。該劑型旨在供吞嚥膠囊困難或偏好顆粒劑型的患者使用。

BioCryst 已將 ORLADEYO 的分銷過渡給 CareMed，作為其獨家專科藥局合作夥伴。管理層表示早期數據顯示新患者首次出貨時間有所縮短。第三季結束時，自費/付費處方率約為 82%-83%，公司認為有機會達到甚至超越 85% 的長期穩定狀態目標。

在產品線方面，Navenibart 的關鍵試驗已於 6 月完成收案。BioCryst 目前正在準備生物製品許可申請（BLA）文件與上市計畫，同時等待 2027 年第三季的 12 個月主要頂線數據。

BCX17725 治療 Netherton 症候群的研究已進入第 4 部分收案。管理層預計 2026 年 12 月將公佈涵蓋療效、安全性及耐受性的數據報告。公司指出，根據內部研究及與主要意見領袖的討論，主要 IASI 評分改善 20%-25% 即可能代表具臨床意義的結果，同時也指出與監管機構的討論仍在進行中。

管理層財測

管理層預期現有業務邁入 2027 年時將維持營收成長，且營業成本基期將低於 2026 年。正式的 2027 年財測將於日後提供。公司亦預計，隨著重組行動的全年效益顯現，2027 年的營業費用將進一步下降。

RAPIVAB 不被視為核心戰略資產。管理層將其描述為低毛利的過渡轉售業務，因此營收貢獻較高對獲利的提振有限。

風險與關注焦點

• 過渡至 CareMed 帶來了暫時性的營運複雜度。管理層僅有六至八週的完整實施經驗，因此對 ORLADEYO 財測保持保守態度。
• 近 2,000 萬美元的庫存貢獻屬於一次性事件。未來季度的營收應更貼近患者需求，但短期內仍可能出現輕微的庫存波動。
• 兒童劑型的採用情況優於初步預期，但上市仍處於初期階段，尚未建立穩定狀態的需求。
• Navenibart 的長期商業機會取決於關鍵試驗數據、監管批准，以及使用其他注射型預防療法的患者的轉用意願。
• BCX17725 的推進將取決於療效、安全性及耐受性數據的整體性與一致性，隨後進行監管討論。

分析師問答亮點

CareMed 庫存影響：管理層確認第三季庫存建立為一次性效益，而非每季重複發生的貢獻。預計 CareMed 將把庫存維持在其典型 7 至 21 天區間的低檔附近。

ORLADEYO 競爭地位：BioCryst 表示，其市場研究對 deucrictibant 進行的模擬設定檔略優於後續的第三期臨床結果。模擬顯示 deucrictibant 可以在不侵蝕 ORLADEYO 現有患者基數的情況下獲取市占率。管理層繼續預期在未來口服競爭產品進入市場後，ORLADEYO 仍能保持成長。

患者留存與控制情況：開始使用 ORLADEYO 的患者中，約 60% 在 12 個月時仍持續接受治療。管理層表示這些患者的病情通常控制良好，並引用真實世界數據顯示發作次數中位數約為每月三分之一次。

Navenibart 給藥頻率：管理層認為每三個月給藥一次具有顛覆性，並認為同時提供 3 個月與 6 個月的給藥頻率可強化產品優勢。根據第二期臨床觀察到的持久性，BioCryst 預期兩種給藥頻率均將納入標籤說明，但仍須視臨床與監管結果而定。

外部創新策略：BioCryst 正在優先考慮早期臨床階段的資產（主要為一期或二期），且具有明確的生物學機制並與其現有的商業化能力相契合。其科學顧問委員會正在與內部科學及業務發展團隊積極審視潛在機會。

完整財報電話會議記錄

---

完整財報電話會議逐字稿

管理層陳述

Operator

Good day, and thank you for standing by. Welcome to the BioCryst Third Quarter 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Nick Wilder with BioCryst. Nick, go ahead.

Nick Wilder

Good morning, and welcome to BioCryst's Third Quarter 2026 Corporate Update and Financial Results Conference Call. Participating with me today are President and CEO, Charlie Gayer; Chief Financial Officer, Babar Ghias; and Chief R&D Officer, Dr. Sandeep Menon. A press release and slide presentation about today's news are available on our Investor Relations website.

Today's call contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to Slide 2 of the presentation.

In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our Investor Relations website.

I'd now like to turn the call over to Charlie.

Charles Gayer

Thanks, Nick. The third quarter was significant for BioCryst as we continue to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for ORLADEYO continued at the same high level that we have seen all year. We again added new prescribers at a rate above the average of the past several years, and the total base of treated patients grew at a healthy rate in the quarter. We were thrilled to launch ORLADEYO pellets to kids in August and early signs of performance continue to be promising. Children of all ages across the 2 to 11 years range have started on ORLADEYO pellets and the mix of kids switching from other prophy and acute only as well as those who were treatment-naive has been balanced. This suggests the pediatric market may grow beyond this 500 patients that we have previously described.

We are also looking forward to launching the recently approved 150-milligram ORLADEYO pellets at the upcoming American College of Allergy, Asthma and Immunology Meeting this month. This new formulation for ages 12 years and up provides an option for kids who started on pellets for adolescents and adults who have difficulty swallowing a capsule or for anyone who simply prefers the pellet formulation. We are looking forward to generating real-world evidence to track the progress and patterns of use for all patients treated with ORLADEYO pellets.

During the third quarter, we also implemented the transition to CareMed as our sole-source pharmacy partner for shipments to patients. We switched to CareMed because the volume of patients on ORLADEYO has grown to the point where operational excellence at the pharmacy level can have a significant impact on the growth in treated patients and the shipment in paid product. We are working closely with CareMed to integrate best practices within our Empower patient services program and are encouraged by the early signs we are seeing in the partnership. We believe CareMed can scale with us as our portfolio of HAE prophy offerings continues to grow.

Turning to our pipeline. As we have previously announced, the pivotal trial for Navenibart fully enrolled in June, and we remain on track to announce top line data through 12 months of therapy in the third quarter of next year. Our team is working diligently on the BLA file as well as launch planning for when we add this potentially transformative product to our HAE portfolio. Continuing on the theme of strong execution, we have enrolled Part 4 of our trial of BCX17725 for Netherton syndrome patients and are on track to have early clinical data by the end of this year. There are no treatments approved for this devastating skin condition that we believe includes at least 3,000 patients in the United States alone.

Once the data reads out, we will review the data in totality, which includes key efficacy endpoints like IASI, the Ichthyosis Area Severity score as well as safety and tolerability to inform potential next steps in the program.

Finally, we are excited about our strategic shift toward building our pipeline through external innovation. We recently announced a Scientific Advisory Board of leading biotech industry experts who will partner with us to deliver on our strategy. These esteemed advisers with a successful track record did not join us just for the honor of being on the Board. They joined us because they believe that BioCryst's profitability, discipline and strong execution position the company for success in our rare disease strategy.

With that, I'll turn it over to Babar to describe our increasingly strong financial position.

Babar Ghias

Thanks, Charlie. We are pleased to share the results of a very strong third quarter, which included not only the important accomplishments just described, but also continued financial excellence. The intentional proactive steps we have taken throughout the year to position BioCryst for durable growth and increasing profitability continue to be reflected in our financial performance.

In my remarks today, I will refer to certain non-GAAP financial measures, which adjust for revenues and expenses associated with our former European ORLADEYO business, stock-based comp, Birmingham site closure and organizational restructuring costs and expenses associated with the Astria acquisition. Additional information regarding these adjustments is included in today's press release. We believe these non-GAAP measures provide investors with a useful view of the underlying performance of the ongoing business.

Now turning first to revenue. ORLADEYO net revenue was $174.8 million for the quarter with more than 95% coming from the U.S. business. On a comparable basis, excluding European revenue, ORLADEYO revenue increased 20% year-over-year. ORLADEYO revenues benefited this quarter from the CareMed transition. One of the benefits of switching to a larger specialty pharmacy is that they maintain a level of inventory at multiple sites and broader set of working operation hours that facilitate timely fulfillment to efficiently respond to patient demand. The inventory they hold typically ranges from 1 to 3 weeks of product. As part of the transition to this model, CareMed built an inventory level towards the lower end of this range during the third quarter, resulting in a revenue contribution in the upper teens of millions of dollars in the quarter.

Since we expect their inventory level to remain in this lower end, revenue should more closely reflect underlying patient demand going forward. While a transition of this nature naturally creates some temporary operational complexity as systems and processes are implemented, we are very pleased with the progress to-date. Although it is still early, we are already seeing an improvement in days to first shipment for new patients, an important measure of the patient experience. Despite the transition, even when removing the impact of the inventory build, ORLADEYO revenue, excluding Europe, grew year-over-year. This is evidence of the continued favorable patient dynamics across the approved population. Throughout this process, our priority has remained the same, maintaining a high-quality patient experience and uninterrupted access to ORLADEYO.

Before turning to operating expenses, let me briefly provide some context around the GAAP to non-GAAP adjustments this quarter. These adjustments primarily relate to the closure of our Birmingham facility and associated organizational restructuring activities that remain on track to be substantially completed by year-end. Of the approximately $19 million in restructuring-related expenses in the quarter, only $10 million are real cash costs. Noncash charges primarily reflected accounting adjustments to assets that no longer will have economic use following the closure. The most important takeaway today is the structural benefit to our cost base. The actions we have taken are expected to generate approximately $30 million to $35 million of annualized savings once fully realized with the potential for additional savings as certain programs are wound down.

As we look towards 2027, the business as it exists today is positioned for continued revenue growth alongside a lower operating cost base than in 2026. We will provide formal 2027 guidance at the appropriate time, but the combination should support continued expansion in profitability.

Turning now over to operating expenses. Non-GAAP operating expenses were slightly lower year-over-year, consistent with the financial discipline we have been emphasizing. We are actively investing in the Phase III development program for Navenibart, which is naturally an important driver of R&D spending. At the same time, we are taking a disciplined data-driven approach to capital allocation across the rest of the pipeline. BCX17725 is a good example. Our approach has been to generate early clinical data in patients first and let that data prospectively inform the appropriate level of future investment. We remain on track to share those data before year-end. Sales and marketing expenses were modestly higher year-over-year, driven primarily by the transition-related fees associated with the Specialty Pharmacy arrangement, and G&A expense has remained essentially flat. This operating leverage from the trend is increasingly visible in our results.

Non-GAAP operating profit for the quarter was $86 million, an increase of 70% year-over-year, while non-GAAP net income of $71 million more than doubled from the prior year period. As profitability continues to grow, we also expect to benefit from our substantial net operating loss carryforwards, which should help limit cash taxes over the medium term, subject to applicable tax rules and limitation. That creates the potential for strong growth, not only in earnings, but also in cash generation. Our liquidity position remains strong with cash and equivalents of $376 million.

As we have discussed, we have made a deliberate pivot towards external innovation, but we are going to remain disciplined in how we build the pipeline. For us, the priority is not adding programs simply to increase the size of the pipeline. It is identifying opportunities where we believe BioCryst can create meaningful value for patients and shareholders. At the same time, we will always continue to evaluate opportunities to strengthen the balance sheet and return capital while maintaining the financial flexibility to invest in compelling innovation.

Turning finally to our 2026 financial guidance. When we established our ORLADEYO revenue guidance, we did not assume a benefit from the initial specialty pharmacy inventory build. Given that we still remain relatively early in the CareMed transition implementation, we are not changing ORLADEYO revenue guidance at this time. We are encouraged by the progress we are seeing, but we also recognize that we are transitioning 6 years of launch experience, systems and operating knowledge from one partner to another on an accelerated time line. Importantly, we view this as a finite transition and not a long-term operating dynamic. Underlying patient demand and trends remain strong, and we are excited about the opportunity to expand the Pediatric launch while also offering the newly approved oral pellet formulation for patients with HAE 12 years and older, providing a continuum of oral treatment options.

On the other hand, we are increasing our total revenue guidance to $715 million to $730 million, reflecting higher realized licensing revenue and international RAPIVAB orders from our partner. To emphasize, RAPIVAB is not a strategic core asset for us and is mostly a pass-through business with low margins. On expenses, we are again tightening our full year operating expense guidance now to $415 million to $425 million for 2026. When we realize the full year benefit of the actions we have taken in 2026, we expect operating expenses in 2027 to decline further while the underlying business continues to grow.

To close, this was a very strong third quarter and strong first 9-months of 2026. We have 1 quarter remaining, and our focus is on finishing the year well and entering 2027 from a position of considerable strength with growing revenue and increasingly efficient cost structure, expanding profitability, strong liquidity and important pipeline catalysts ahead, we believe we have the opportunity to make 2027 a transformational year for BioCryst. The entire organization is focused on executing against the opportunity, and I am very grateful to our colleagues across BioCryst for everything they have accomplished this year.

With that, operator, we are now ready to take questions.

Operator

[Operator Instructions] Our first question comes from the line of Gavin Clark-Gartner with Evercore ISI.

分析師問答

Gavin Clark-Gartner

Great to see the progress. I guess, first, just to clarify on the inventory. So there was upper teens contribution from the CareMed inventory build. How should we expect that to trend next quarter? Like will there be a reversal of a similar amount? Is there some level of inventory build still to happen here? Like what should we think about next quarter?

Babar Ghias

Yes. Thanks for the question, Gavin. So I think your intuition is correct. It's a onetime inventory build that they have to [indiscernible] for dispensing. And our expectation is that, as I mentioned in the call, that typically, they hold 7 to 31 days of -- 7 to 21 days of inventory. And in this quarter, we were on the lower side of that range, and we expect that to remain in the lower side. So you're not going to expect a onetime benefit or, I guess, a recurring benefit of inventory every quarter from this point onwards. There may be in the nearer term, in another quarter, there may be small fluctuations. But as it gets smoothed out, it should reflect patient demand. So to summarize, it was really a onetime benefit of this order of magnitude, and that should be the expectation.

Gavin Clark-Gartner

Okay. Great. That's helpful. And just a quickly quick follow-up. What was the pediatric prescriptions that you saw this quarter?

Charles Gayer

We're not going to get into the specific numbers, Gavin, but it continued to be strong. We announced at the end -- I think it was at the end of July, we had 47. That was well ahead of our expectations for the year. We continue ahead of our expectations. The pediatric revenue we generate is still going to be a very small part of this year's revenue, but it's a good sign for the future. And like I mentioned, we're looking forward to starting to collect real-world evidence in this population. So I think we'll have more to report out in the future as a little more time passes.

Operator

Our next question comes from the line of Laura Chico at Wedbush.

Laura Chico

I guess I wanted to ask one more strategic. Could you expand on your commentary around the 2033 and beyond outlook for the HAE franchise? If I'm looking at the slides correctly, it looks like you're describing it as a range from about $1.4 billion to $2.0 billion in 2033. I think before you talked about this as a $1.8-plus billion opportunity. So I guess help us understand some of the dynamics there that go into the lower and upper bounds. What needs to go right? And I guess, has anything changed to shift your outlook?

Charles Gayer

Thanks, Laura. Yes, the range that we provide is actually based on sell-side analyst views of the portfolio. And we put it out there because directionally, we agree with the two products with the most established oral at that point, the market-leading oral prophy and then what we think will be really a transformative product with every 3- and 6-month dosing with navenibart, it really allows us to hit both big segments of the market, those who prefer oral prophy, those who prefer injectable prophy.

And so the things that need to go right for that to happen, obviously, is continued growth of ORLADEYO, which we expect and all of our forward-looking research metrics tell us that, that will continue. And then a strong launch that we're preparing for, for Navenibart. And what we see in our research with doctors and patients is that, that 3- and 6-month dosing with high efficacy and with a convenient administration is something that gets their attention and will encourage patients to switch. So the real key is going to be how many of the patients who are on other injectable prophies want to take advantage of this longer-term dosing and switch. That will be the key driver of kind of the pace of our revenue growth and kind of the ultimate peak of where we get with Navenibart.

Operator

Our next question comes from the line of Steve Seedhouse at Cantor.

Steven Seedhouse

Sort of related to the long-term revenue projections, but specifically as it pertains to ORLADEYO and just the stickiness of that, have you guys done any updated market research post the Deucrictibant Prophylaxis Phase III result? And do you have a sense if that was above, below or sort of in line with expectations of what you've been modeling really for the past several years?

Charles Gayer

Thanks, Steve. We have not done specific research since the data came out. However, what we did do is our annual large exercise that we do every -- in the middle of every year, where we talk to 175 HAE treaters, 100 patients, 50 payers and run it through a big conjoint exercise and market simulation model. What we put in there for deucrictibant, recall that we always put all of our current and future competition in, with their best case profile. And so the profile that we put in for deucrictibant was actually slightly better than the actual -- what they proved out in the Phase III. So comparable but slightly better.

And it showed that, yes, that product will gain share, as you would expect, but what it's not going to do is take away the base of ORLADEYO patients. And so we continue to see ORLADEYO growing even in the face of future competition in a couple of years from deucrictibant.

Operator

Our next question comes from the line of Stacy Ku at TD Cowen.

Stacy Ku

We have a couple of clarifications. So first, maybe can you talk about your -- given your inventory commentary, I really appreciate all the detailed thoughts there, your level of confidence in the high end of ORLADEYO guidance that you provided for the year. This is just a follow-up on inventory. And then second, on the pediatric launch, is it -- would you characterize it more as steady additions? Or are you seeing a bit of a bolus type of dynamic for the pediatric prescriptions?

As we look to next year and consensus, I know you won't comment, but does that include what you're seeing for the pediatric launch? Or would you look at that as upside? And then third clarification. When we speak to clinicians, they tend to have their patients track very detailed data on their attacks for payer reimbursement access. So as you're looking at the oral competitive landscape in the next couple of years, do you have a good sense of the percentage of patients that are well controlled on ORLADEYO, so having really competitive attack rate reductions as folks try to understand the stickiness of the drug?

Charles Gayer

Great. Thanks, Stacy. Maybe I'll take -- go through the second question with all those pieces, and then we'll come back and Babar can talk about the inventory.

So on the pediatrics, so number one, its -- what we're seeing is kind of steady, strong additions. So there was, of course, a bolus at first, particularly because of the supply delay that we had. So there was a bolus to start. Those patients have been transitioned to therapy. And then we're seeing continued strong demand that is ahead of what our original expectations are. It's still only been a few months. So we'll have to see how long this continues, but the early signs are very promising. As we kind of look to the future of ORLADEYO and when we give guidance for 2027, pediatrics will be absolutely a part of all of that. And then when we have additional data that, as I mentioned, real-world evidence, when we generate other evidence that we think is interesting and helpful, we may comment on other pieces of how pediatrics breaks out of the whole bit.

And then as far as the patients who are well-controlled on ORLADEYO, you've heard us talk before about when patients start, 60% of them roughly get to 12 months of therapy. And then those patients are largely the very well controlled. And so those are the ones who are getting down to a median attack rate. We've put out real-world evidence on this where they're getting down to a median attack rate of about 1/3 of an attack per month and patients generally are reporting significant reductions in attack rates regardless of where they're coming from, whether they switch from other prophy or not previously on-prophy. And so we feel like we're holding on to the patients who are doing well. They're getting market competitive efficacy. So then Babar, do you want to talk about the...

Babar Ghias

Yes. So thanks, Stacy, for the question. Allow me to explain a little bit more perspective on the pharmacy. So look, at the end of the day, the progress of any product should be on patient demand and not inventory dynamics. And as we -- as Charlie mentioned in his remarks that the performance of a pharmacy can actually create a meaningful impact on the progress of these products. And when we made that switch, we were getting to a point of scaling the product that we needed to move with a larger partner who can support the vision for ORLADEYO and potentially Navenibart when it gets approved. So when we think about basically keeping the guidance as we -- at the start of the year, we had a different pharmacy partner. We had a different operating model. It was not necessarily incorporating the dynamics of the inventory.

As I said, what we don't want to do is artificially change the guidance because fundamentally, it should be about patient demand. So we are still in early days of that. So we didn't feel the need that at this point in time, we need to change the guidance for ORLADEYO just because we have a onetime inventory dynamic. And as I said, that once we get past this quarter, as you can appreciate, it's only been 6 weeks that we've actually been like fully with CareMed because the implementation started somewhere in the August time frame. So call it, 6 weeks to 8 weeks. We don't even have a full quarter under the belt. So as we get past through that, it should really reflect the patient demand. So that's why we were being a little bit careful and being conservative in terms of changing guidance at this point in time just because of an inventory dynamic.

Operator

Our next question comes from the line of Tazeen Ahmad with Bank of America.

Jeremiah Lorentz

This is Jeremiah on for Tazeen. I wanted to ask a question on the Netherton readout that's expected around year-end. I'm just wondering what's the benchmark or what level of data you guys are looking for in order to move that program forward? And I guess, depending on if the study [is a hit], how quickly could you move to pivotal stages?

Charles Gayer

Sandeep, do you want to take that?

Sandeep Menon

Yes, I'll take that. Thank you for the question. As you know, Netherton syndrome is a devastating skin disease and that has got multiple other layers of disease manifestation, including immunity and inflammation. We are getting ready for our data readout in December. What we will be presenting is the primary endpoint and the key secondary endpoints along with obviously the safety and tolerability of that. And what good looks like at this point, these patients don't have any treatment options. And given the severity of the disease, any improvement, which is clinically meaningful is still better than what patients don't have at this point.

So we have talked to the patients and the relevant KOLs and also in discussions very soon with the FDA to come up with a benchmark basically. But from our perspective, as long as we are able to get 20% to 25% in the primary IAZ score, I think it should be a pretty good clinically meaningful endpoint based on all the research that we have done internally, talking to the KOLs and obviously, the regulatory discussions are pending as well. So I think we'll put it out there for now. And once the data reads out, we'll share more.

Charles Gayer

Obviously, within that, we'll be looking for kind of consistency of effect as well. And so we'll look at this in a number of different ways. Do you want to just talk about -- what do we think next will be with the [indiscernible].

Sandeep Menon

Yes. The next -- basically, we will be reflecting on the totality of the data. And at this point, we want to do what is best for the program and for the patients. So we are not going to rush into anything that is a pivotal right away. Depending on what the data is, we'll talk to the regulators and digest the data because this is going to be the first-in-class, first therapy ever coming for Netherton. We want to be very clear in terms of where we want to take this. But we will be swift in decision-making, and we will move fast to be -- at the same time, we will be very scientifically rigorous and thoughtful in how we take the clinical development forward.

Operator

Our next question comes from the line of Maury Raycroft with Jefferies.

Maurice Raycroft

I'll shift gears and maybe just ask one on BD. I guess with the new Scientific Advisory Board, can you talk more about their mandate and what your latest thinking is related to BD and the type of assets you're looking to in-license?

Sandeep Menon

Yes. So from our -- thank you for the question, Maurice. So our Scientific Advisory Board, as you can see, it comes with a high pedigree and a very, very successful track record, including with Dr. Tony Manning, who is chairing the SAB. So it is a working Scientific Advisory Board, like Charlie mentioned. It is not that people are coming in to get some luxurious seat on the Board here. They are working with us, as we are -- at least a few times a week. We are rolling our sleeves, looking at multiple assets. As we have shared before, it's going to be early clinical assets, Phase I, Phase II. Mostly we'll go with a very, very clear biology.

We are not going to take chances on things that are far-fetched in terms of an inflection point. And we will ensure that this is sticking to our core strengths because we have a commercial fabric that we are going to take advantage of. So that is what we are going to play. And you will see in the next few months as we have more information, we'll be ready to share. But the punchline here is the SAB is very, very seasoned. They have been there, done that, and we are working together as a team to get to a place where we have a pipeline that is going to be rich and valuable to our stakeholders.

Charles Gayer

And Maury, just to add to that, too, we've, of course, built a very strong internal team for both scientific evaluation and business development. So the internal team is generating the ideas. And then when we get excited about something, the SAB helps us really wrestle it to the ground, -- this is something that we want to do. So we think it's a great partnership. Early days, it's working very well, and we think that this is going to be very supportive to our strategy.

Maurice Raycroft

Got it. That's helpful. And maybe just a quick follow-up on Netherton. As you guys are thinking about next steps with the program. In the press release, you mentioned that expenses were lower related to the program in third quarter. I guess any specific reasons there? Is it just because the study is enrolled and it's kind of at a status quo? Or how should we think about that?

Babar Ghias

Yes. And I think I will point it back to the financial discipline that we have been instituting across the organization, Maury, and basically taking an evidence-based approach. So I'll give you an example, like historically, we may have been a little bit aggressive in our sense that like we need to do CMC campaign before we've actually seen results. I think what I was basically emphasizing earlier was we're taking a very evidence-based and rigorous scientific approach that do we first have a product? Do we have the available data that allows us to unlock the next step of development.

So I think across the organization, we've been instituting that discipline. And in Netherton like I said, that was a perfect example where we didn't feel that we need to spend dollars at risk on things before we actually can unlock the data. So that was basically the primary reason why you see a decline in expense. And I think that is going to be a theme, right? That is how we're going to go about and develop on this innovation aspect that we're talking about BD, but also being very committed to delivering strong profitability going forward.

Sandeep Menon

And Maury, just to add what Barba nicely summarized, we will ensure that we are still very swift. It's not that we are going to just make it so sequential that we will delay the program. And that's not what it is. Basically, we will get some early data and we'll take the right bets that is going to give us scientific and development success.

Operator

The next question comes from the line of Jessica Fye with JPMorgan.

Unknown Analyst

This is Sylvia on for Jeff Fye. To confirm with the prior model pre-CareMed, was there any inventory sitting elsewhere that needs to be worked down that maybe leads to the hesitation to update the ORLADEYO guide?

And as a follow-up, and I appreciate the conservatism so soon after the specialty pharmacy shift. But if the high teens inventory benefit was not contemplated in the fundamental ORLADEYO guidance you laid out and are maintaining, would it be wrong for investors to expect full year ORLADEYO revenue landing in the $650 million to $655 million range? Which is just the midpoint of the fundamental guidance plus $15 million to $20 million.

Charles Gayer

Thanks, Sylvia. First of all, from inventory from the prior pharmacy, the billing model was different there. It was -- there was a flash sale for every pack that went out. So there basically was no inventory. And then with CareMed, it's a little bit more traditional pharmacy model where they buy some inventory. And as Babar described, it's at a relatively low level, about a week's worth of inventory. And now, from the guidance perspective, with everything we see at this point and with the changes that as we're saying, we still haven't worked through completely, we see the range of $625 million to $645 million is still the right guidance for the year.

Operator

Our next question comes from the line of Serge Belanger.

John Todaro

This is John on for Serge today. Just a couple on ORLADEYO. First, curious if you could provide an update on the paid Rx rate exiting the third quarter? And if your outlook has changed on where this could reach considering the efficiencies yielded from the CareMed partnership?

And then second, on the pediatric side of things, you highlighted the launch is progressing ahead of expectations. Just curious how you view the overall opportunity now versus the original 500 patient pool?

Charles Gayer

Thanks, John. As far as the paid rate, just recall, what typically happens in the second half of the year is, our paid rate typically peaks in the second quarter after going through all the reauthorizations in the first part of the year. And then in the second half of the year, it starts to gradually tick down mainly because the rate is driven more by new patients coming on and new patients don't get to the 80-plus percent paid rate that we have in the overall population as quickly. So we're seeing that same dynamic right in line with our expectations. I think we ended the quarter somewhere around 82%, 83% paid.

To your question around CareMed, we do think there -- with their capabilities working with our team, it gives us the opportunity to meet and potentially exceed our long-term goal of getting to 85% paid rate as kind of a steady state. So we think we're on track for that.

I'll note that with pediatrics, too, we're seeing excellent early paid rates. Pediatrics, as you would expect, is basically a commercial plus Medicaid business, so a little bit different dynamic than our overall population. But the early signs are we're getting these kids at a high rate to paid and I expect that to continue. And then as far as the overall opportunity for paed, yes, we're cautiously optimistic that it could end up being bigger than we originally expected. It certainly is turning out to be that this year. I think we need a couple of quarters -- in addition, at least to see what the steady state is in terms of demand. There's still physicians out there who are still learning about this indication and haven't acted yet. And so I think there's likely a lot more opportunity than the 500 diagnosed and treated patients that we've previously described.

Operator

Our next question comes from the line of Jon Wolleben at Citizens.

Catherine Okoukoni

This is Catherine on for Jon. I have a quick clarification question about the number of patient adds. I know you said that the patient adds have been kind of tracking along the average -- from like quarter-by-quarter. I just wanted to provide a little bit more color on how that's tracking and how -- what your expectations are for fourth quarter based on your revenue guidance?

Charles Gayer

Thanks, Catherine. Yes, what we described is that new patient prescriptions coming in has been very much in line. And then the net patient adds in the third quarter were quite healthy. So we expect [ particularly ] with our transition to CareMed with the continued demand with the strong demand in paeds that we would expect another good quarter in the fourth quarter and that this trend will largely continue into 2027.

Operator

Our next question comes from the line of Brian Abrahams at RBC Capital Markets.

Brian Abrahams

I'm curious, are you seeing any effects on ORLADEYO use patterns from the recent launch of oral on-demand or other long-acting injectable therapies for prophylaxis? And then I guess, secondarily, curious what your market research tells you about the potential opportunity differences if Navenibart can demonstrate every 6-month dosing versus every 3 months?

Charles Gayer

Thanks, Brian. We've said before, and at this point, it's been over a year since those -- since the oral acute came on to the market and then also the 2 new prophies that came on last summer. We're really not seeing any impact from the oral acute patients. Some ORLADEYO patients are using it. We're certainly not seeing any negative trends nor would I say it's anything particularly positive. It just hasn't had that much of an impact on our business. The oral -- or sorry, the other longer-acting injectables -- what we're really seeing there is that when a patient ORLADEYO doesn't work out for them, instead of moving preferentially to Takhzyro, more of those patients are going either to Andembry or Dawnzera, that's what you would expect.

And then with Navenibart, what we're seeing, again, in all the research that we've done, 3 months is -- is really a transformative -- every 3-month dosing is really transformative. And then having the ability to have 3-months and 6-months as an option makes the whole package even better. And so we expect to get both doses in our label based on -- certainly based on the Phase II data that we've seen with both doses having very durable reduction in attacks. And so to have that option, we don't know yet which dosage form would be -- which frequency would be most used. I think that's something we'll learn more about. But to have both really makes Navenibart a very strong option for patients and physicians, very really, really intriguing to them.

Operator

This concludes the question-and-answer session. I would now like to turn it back to Charlie Gayer for closing remarks.

Charles Gayer

Thank you. So as we've described here, another really strong quarter for BioCryst as we've gone through a year of transformation, both in leadership, in strategy, in how we run the business. And I'd also like to thank everybody, all our colleagues at BioCryst who've worked so hard during this year of transition. And I think we've set ourselves up for a really great 2027 and beyond. So thank you, everyone.

Operator

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.